A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (NCT05142696)
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
🩺 Plain-English Summary (8th-Grade Level)
This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.
Who can join: Review the eligibility criteria below.
Location: AdventHealth — Orlando, Florida
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- AdventHealth — Orlando, Florida
- University Cancer and Blood Center LLC — Athens, Georgia
- University of Kentucky — Lexington, Kentucky
- St Louis University — St Louis, Missouri
- Hackensack University Medical Ctr — Hackensack, New Jersey
- University Hospitals Of Cleveland — Cleveland, Ohio
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Novartis Investigative Site — Vienna,
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Beijing,
- Novartis Investigative Site — Shanghai,
- Novartis Investigative Site — Olomouc,
- Novartis Investigative Site — Lille,
- Novartis Investigative Site — Marseille,
- Novartis Investigative Site — Montpellier,
- Novartis Investigative Site — Essen,
- Novartis Investigative Site — Beersheba,
- Novartis Investigative Site — Ramat Gan,
- Novartis Investigative Site — Tel Aviv,
- Novartis Investigative Site — Singapore,
- Novartis Investigative Site — Seoul,
- Novartis Investigative Site — Seoul,
- Novartis Investigative Site — Barcelona,
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Madrid,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Extensive Stage Small Cell Lung Cancer
- To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC — Birmingham, Alabama
- First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) — Los Angeles, California
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer — Chicago, Illinois
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) — Los Angeles, California
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) — Gilbert, Arizona
Explore by condition: All Extensive Stage Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.